These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ý
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
Delaware
|
52-2107911
|
|
(State of incorporation)
|
(I.R.S. Employer Identification No.)
|
|
Large accelerated filer
|
ý
|
Accelerated filer
|
o
|
|
|
Non-accelerated filer
|
o
|
Smaller reporting company
|
o
|
|
Page
|
||
|
PART I – FINANCIAL INFORMATION
|
||
|
Item 1.
|
Financial Statements:
|
|
|
Item 2.
|
||
|
Item 3.
|
||
|
Item 4.
|
||
|
PART II – OTHER INFORMATION
|
||
|
Item 1.
|
||
|
Item 1A.
|
||
|
Item 2.
|
||
|
Item 6.
|
||
|
September 30,
2010
|
December 31,
2009
|
|||||||
|
ASSETS
|
||||||||
|
Current Assets
|
||||||||
|
Cash and cash equivalents
|
$ | 146.1 | $ | 131.3 | ||||
|
Accounts receivable, net
|
228.0 | 191.4 | ||||||
|
Inventories
|
1,472.8 | 1,301.2 | ||||||
|
Deferred income taxes
|
43.4 | 48.6 | ||||||
|
Deferred costs associated with deferred revenue
|
184.5 | 244.4 | ||||||
|
Other current assets
|
61.1 | 52.7 | ||||||
|
Total Current Assets
|
2,135.9 | 1,969.6 | ||||||
|
Property, Plant and Equipment, net
|
1,195.3 | 1,115.1 | ||||||
|
Other Long-Term Assets
|
||||||||
|
Deferred income taxes
|
240.6 | 270.3 | ||||||
|
Deposits for surety bonds
|
110.2 | 158.3 | ||||||
|
Deferred financing costs, net
|
10.5 | 12.0 | ||||||
|
Goodwill
|
6.8 | 6.8 | ||||||
|
Total Other Long-Term Assets
|
368.1 | 447.4 | ||||||
|
Total Assets
|
$ | 3,699.3 | $ | 3,532.1 | ||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
|
Current Liabilities
|
||||||||
|
Accounts payable and accrued liabilities
|
$ | 148.1 | $ | 153.4 | ||||
|
Payables under Russian Contract
|
231.4 | 134.8 | ||||||
|
Inventories owed to customers and suppliers
|
587.1 | 469.4 | ||||||
|
Deferred revenue and advances from customers
|
237.6 | 325.0 | ||||||
|
Total Current Liabilities
|
1,204.2 | 1,082.6 | ||||||
|
Long-Term Debt
|
575.0 | 575.0 | ||||||
|
Series B-1 12.75% Convertible Preferred Stock
|
75.8 | - | ||||||
|
Other Long-Term Liabilities
|
||||||||
|
Depleted uranium disposition
|
119.2 | 155.6 | ||||||
|
Postretirement health and life benefit obligations
|
173.8 | 168.9 | ||||||
|
Pension benefit liabilities
|
181.5 | 176.6 | ||||||
|
Other liabilities
|
84.2 | 97.8 | ||||||
|
Total Other Long-Term Liabilities
|
558.7 | 598.9 | ||||||
|
Commitments and Contingencies (Note 14)
|
||||||||
|
Stockholders’ Equity
|
1,285.6 | 1,275.6 | ||||||
|
Total Liabilities and Stockholders’ Equity
|
$ | 3,699.3 | $ | 3,532.1 | ||||
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2010
|
2009
|
2010
|
2009
|
|||||||||||||
|
Revenue:
|
||||||||||||||||
|
Separative work units
|
$ | 404.2 | $ | 467.0 | $ | 1,001.8 | $ | 1,266.2 | ||||||||
|
Uranium
|
79.3 | 26.2 | 164.5 | 150.2 | ||||||||||||
|
U.S. government contracts and other
|
81.1 | 56.1 | 202.7 | 152.8 | ||||||||||||
|
Total revenue
|
564.6 | 549.3 | 1,369.0 | 1,569.2 | ||||||||||||
|
Cost of sales:
|
||||||||||||||||
|
Separative work units and uranium
|
451.4 | 461.3 | 1,077.2 | 1,268.1 | ||||||||||||
|
U.S. government contracts and other
|
75.2 | 48.8 | 183.0 | 142.3 | ||||||||||||
|
Total cost of sales
|
526.6 | 510.1 | 1,260.2 | 1,410.4 | ||||||||||||
|
Gross profit
|
38.0 | 39.2 | 108.8 | 158.8 | ||||||||||||
|
Special charge for workforce reduction
|
- | 2.5 | - | 2.5 | ||||||||||||
|
Advanced technology costs
|
28.6 | 31.7 | 80.3 | 93.8 | ||||||||||||
|
Selling, general and administrative
|
14.0 | 14.0 | 43.4 | 45.1 | ||||||||||||
|
Other (income)
|
(12.4 | ) | - | (32.4 | ) | - | ||||||||||
|
Operating income (loss)
|
7.8 | (9.0 | ) | 17.5 | 17.4 | |||||||||||
|
Preferred stock issuance costs
|
4.8 | - | 4.8 | - | ||||||||||||
|
Interest expense
|
0.3 | 0.2 | 0.4 | 1.0 | ||||||||||||
|
Interest (income)
|
(0.2 | ) | (0.2 | ) | (0.4 | ) | (1.2 | ) | ||||||||
|
Income (loss) before income taxes
|
2.9 | (9.0 | ) | 12.7 | 17.6 | |||||||||||
|
Provision (benefit) for income taxes
|
1.9 | (2.8 | ) | 14.2 | 8.6 | |||||||||||
|
Net income (loss)
|
$ | 1.0 | $ | (6.2 | ) | $ | (1.5 | ) | $ | 9.0 | ||||||
|
Net income (loss) per share – basic
|
$ | .01 | $ | (.06 | ) | $ | (.01 | ) | $ | .08 | ||||||
|
Net income (loss) per share – diluted
|
$ | .01 | $ | (.06 | ) | $ | (.01 | ) | $ | .06 | ||||||
|
Weighted-average number of shares outstanding:
|
||||||||||||||||
|
Basic
|
113.2 | 111.8 | 112.6 | 111.3 | ||||||||||||
|
Diluted
|
166.4 | 111.8 | 112.6 | 160.0 | ||||||||||||
|
Nine Months Ended
September 30,
|
||||||||
|
2010
|
2009
|
|||||||
|
Cash Flows from Operating Activities
|
||||||||
|
Net income (loss)
|
$ | (1.5 | ) | $ | 9.0 | |||
|
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
|
||||||||
|
Depreciation and amortization
|
30.2 | 23.2 | ||||||
|
Deferred income taxes
|
31.9 | (0.1 | ) | |||||
|
Other non-cash income on release of disposal obligation
|
(32.4 | ) | - | |||||
|
Preferred stock issuance costs and capitalized paid-in-kind dividends
|
5.6 | - | ||||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Accounts receivable – (increase)
|
(36.6 | ) | (10.6 | ) | ||||
|
Inventories – (increase) decrease
|
(53.9 | ) | 212.7 | |||||
|
Payables under Russian Contract – increase
|
96.6 | 33.4 | ||||||
|
Deferred revenue, net of deferred costs – increase (decrease)
|
4.1 | (26.4 | ) | |||||
|
Accrued depleted uranium disposition – increase (decrease)
|
(36.4 | ) | 28.3 | |||||
|
Accounts payable and other liabilities – increase
|
8.5 | 22.9 | ||||||
|
Other, net
|
13.9 | 27.0 | ||||||
|
Net Cash Provided by Operating Activities
|
30.0 | 319.4 | ||||||
|
Cash Flows Used in Investing Activities
|
||||||||
|
Capital expenditures
|
(123.0 | ) | (363.2 | ) | ||||
|
Deposits for surety bonds – (increase) decrease
|
48.1 | (38.2 | ) | |||||
|
Net Cash (Used in) Investing Activities
|
(74.9 | ) | (401.4 | ) | ||||
|
Cash Flows Used in Financing Activities
|
||||||||
|
Borrowings under credit facility
|
38.3 | - | ||||||
|
Repayments under credit facility
|
(38.3 | ) | - | |||||
|
Repayment and repurchases of senior notes
|
- | (95.7 | ) | |||||
|
Proceeds from issuance of Series B-1 convertible preferred stock and warrants
|
75.0 | - | ||||||
|
Payments for deferred financing costs and preferred stock issuance costs
|
(13.2 | ) | (0.7 | ) | ||||
|
Common stock issued (purchased), net
|
(2.1 | ) | (0.8 | ) | ||||
|
Net Cash Provided by (Used in) Financing Activities
|
59.7 | (97.2 | ) | |||||
|
Net Increase (Decrease)
|
14.8 | (179.2 | ) | |||||
|
Cash and Cash Equivalents at Beginning of Period
|
131.3 | 248.5 | ||||||
|
Cash and Cash Equivalents at End of Period
|
$ | 146.1 | $ | 69.3 | ||||
|
Supplemental Cash Flow Information:
|
||||||||
|
Interest paid, net of amount capitalized
|
$ | - | $ | 5.6 | ||||
|
Income taxes paid, net of refunds
|
2.7 | 5.3 | ||||||
|
September 30,
2010
|
December 31,
2009
|
|||||||
|
(millions)
|
||||||||
|
Current assets:
|
||||||||
|
Separative work units
|
$ | 991.3 | $ | 805.1 | ||||
|
Uranium
|
468.6 | 482.1 | ||||||
|
Materials and supplies
|
12.9 | 14.0 | ||||||
| 1,472.8 | 1,301.2 | |||||||
|
Current liabilities:
|
||||||||
|
Inventories owed to customers and suppliers
|
(587.1 | ) | (469.4 | ) | ||||
|
Inventories, net
|
$ | 885.7 | $ | 831.8 | ||||
|
December 31,
2009
|
Capital Expenditures
(Depreciation
)
|
Transfers
and
Retirements
|
September 30,
2010
|
|||||||||||||
|
Construction work in progress
|
$ | 991.4 | $ | 102.9 | $ | (11.2 | ) | $ | 1,083.1 | |||||||
|
Leasehold improvements
|
182.6 | - | 3.0 | 185.6 | ||||||||||||
|
Machinery and equipment
|
260.1 | 2.2 | 8.1 | 270.4 | ||||||||||||
| 1,434.1 | 105.1 | (0.1 | ) | 1,539.1 | ||||||||||||
|
Accumulated depreciation and amortization
|
(319.0 | ) | (24.9 | ) | 0.1 | (343.8 | ) | |||||||||
| $ | 1,115.1 | $ | 80.2 | $ | - | $ | 1,195.3 | |||||||||
|
September 30,
2010
|
December 31,
2009
|
|||||||
|
(millions)
|
||||||||
|
Deferred revenue
|
$ | 222.5 | $ | 301.9 | ||||
|
Advances from customers
|
15.1 | 23.1 | ||||||
| $ | 237.6 | $ | 325.0 | |||||
|
September 30,
|
December 31,
|
|||||||
|
2010
|
2009
|
|||||||
|
(millions)
|
||||||||
|
Short-term borrowings
|
$ | - | $ | - | ||||
|
Letters of credit
|
42.6 | 45.4 | ||||||
|
Available credit
|
207.4 | 295.5 | ||||||
|
September 30, 2010
|
||||
|
Series B-1 12.75% convertible preferred stock:
|
||||
|
Value at issuance
|
$ | 75.0 | ||
|
Dividends payable
|
0.8 | (a) | ||
|
Balance as of September 30, 2010
|
$ | 75.8 | ||
|
(a) Paid-in-kind dividends of approximately 770 shares of convertible preferred stock declared payable on October 1, 2010.
|
||||
|
•
|
Level 1 – quoted prices in active markets for identical assets or liabilities.
|
|
•
|
Level 2 – inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.
|
|
•
|
Level 3 – unobservable inputs in which little or no market data exists.
|
|
Fair Value Measurements
(in millions)
|
||||||||||||||||||||||||||||||||
|
September 30, 2010
|
December 31, 2009
|
|||||||||||||||||||||||||||||||
|
Level 1
|
Level 2
|
Level 3
|
Total
|
Level 1
|
Level 2
|
Level 3
|
Total
|
|||||||||||||||||||||||||
|
Assets:
|
||||||||||||||||||||||||||||||||
|
Deferred compensation asset (a)
|
- | $ | 1.7 | - | $ | 1.7 | - | $ | 1.5 | - | $ | 1.5 | ||||||||||||||||||||
|
Liabilities:
|
||||||||||||||||||||||||||||||||
|
Deferred compensation obligation (a)
|
- | 1.8 | - | 1.8 | - | 1.5 | - | 1.5 | ||||||||||||||||||||||||
|
Series B-1 12.75% convertible preferred stock (b)
|
- | - | 75.0 | 75.0 | - | - | - | - | ||||||||||||||||||||||||
|
(a)
The deferred compensation obligation represents the balance of deferred compensation plus net investment earnings. The deferred compensation plan is informally funded through a rabbi trust using variable universal life insurance. The cash surrender value of the life insurance policies is designed to track the deemed investments of the plan participants. Investment crediting options consist of institutional and retail investment funds. The deemed investments are classified within level 2 of the valuation hierarchy because of (i) the indirect method of investing and (ii) unit prices of institutional funds are not quoted in active markets; however, the unit prices are based on the underlying investments which are traded in active markets.
|
||||||||||||||||||||||||||||||||
|
(b)
The calculation of the fair value allocated to the Series B-1 12.75% convertible preferred stock included unobservable (level 3) inputs as described in Note 7.
|
||||||||||||||||||||||||||||||||
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2010
|
2009
|
2010
|
2009
|
|||||||||||||
|
Series B-1 12.75% convertible preferred stock:
|
||||||||||||||||
|
Beginning balance
|
$ | - | $ | - | $ | - | $ | - | ||||||||
|
Total gains or losses (realized/unrealized)
|
- | - | - | - | ||||||||||||
|
Purchases, issuances, sales and settlements:
|
||||||||||||||||
|
Purchases
|
- | - | - | - | ||||||||||||
|
Issuances
|
75.0 | - | 75.0 | - | ||||||||||||
|
Paid in kind dividends payable
|
0.8 | - | 0.8 | - | ||||||||||||
|
Sales
|
- | - | - | - | ||||||||||||
|
Settlements
|
- | - | - | - | ||||||||||||
|
Ending balance
|
$ | 75.8 | $ | - | $ | 75.8 | $ | - | ||||||||
|
Common
Stock,
Par Value
$.10 per
Share
|
Excess of
Capital over
Par Value
|
Retained
Earnings
|
Treasury
Stock
|
Accumulated
Other Compre-hensive
Income (Loss)
|
Total
Stockholders’
Equity
|
Compre-hensive
Income (Loss)
|
||||||||||||||||||||||
|
Balance at December 31, 2009
|
$ | 12.3 | $ | 1,179.6 | $ | 322.4 | $ | (71.3 | ) | $ | (167.4 | ) | $ | 1,275.6 | ||||||||||||||
|
Restricted and other stock issued, net
|
- | (8.3 | ) | - | 13.8 | - | 5.5 | - | ||||||||||||||||||||
|
Amortization of actuarial losses and prior service costs (credits), net of income tax of $3.0 million
|
- | - | - | - | 6.0 | 6.0 | 6.0 | |||||||||||||||||||||
|
Net (loss)
|
- | - | (1.5 | ) | - | - | (1.5 | ) | (1.5 | ) | ||||||||||||||||||
|
Balance at September 30, 2010
|
$ | 12.3 | $ | 1,171.3 | $ | 320.9 | $ | (57.5 | ) | $ | (161.4 | ) | $ | 1,285.6 | $ | 4.5 | ||||||||||||
|
|
Defined Benefit Pension Plans
|
Postretirement Health and Life Benefits Plans
|
||||||||||||||||||||||||||||||
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||||||||||||||||
|
2010
|
2009
|
2010
|
2009
|
2010
|
2009
|
2010
|
2009
|
|||||||||||||||||||||||||
|
Service costs
|
$ | 4.8 | $ | 4.7 | $ | 14.5 | $ | 14.0 | $ | 1.2 | $ | 1.2 | $ | 3.7 | $ | 3.5 | ||||||||||||||||
|
Interest costs
|
12.3 | 11.9 | 36.7 | 35.7 | 3.0 | 3.2 | 8.9 | 9.5 | ||||||||||||||||||||||||
|
Expected return on plan assets(
gains)
|
(12.2 | ) | (10.6 | ) | (36.6 | ) | (31.9 | ) | (0.9 | ) | (0.8 | ) | (2.7 | ) | (2.3 | ) | ||||||||||||||||
|
Amortization of prior service costs
(credits)
|
0.4 | 0.4 | 1.3 | 1.2 | (2.1 | ) | (3.6 | ) | (6.3 | ) | (10.8 | ) | ||||||||||||||||||||
|
Amortization of actuarial losses
|
4.0 | 6.0 | 12.0 | 18.0 | 0.7 | 1.0 | 2.0 | 3.1 | ||||||||||||||||||||||||
|
Net benefit costs
|
$ | 9.3 | $ | 12.4 | $ | 27.9 | $ | 37.0 | $ | 1.9 | $ | 1.0 | $ | 5.6 | $ | 3.0 | ||||||||||||||||
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2010
|
2009
|
2010
|
2009
|
|||||||||||||
|
(millions)
|
||||||||||||||||
|
Total stock-based compensation costs:
|
||||||||||||||||
|
Restricted stock and restricted stock units
|
$ | 1.3 | $ | 1.4 | $ | 6.2 | $ | 6.0 | ||||||||
|
Stock options, performance awards and other
|
0.4 | 0.3 | 1.5 | 1.3 | ||||||||||||
|
Less: costs capitalized as part of inventory
|
(0.1 | ) | - | (0.3 | ) | (0.2 | ) | |||||||||
|
Expense included in selling, general and administrative
|
$ | 1.6 | $ | 1.7 | $ | 7.4 | $ | 7.1 | ||||||||
|
Total after-tax expense
|
$ | 1.1 | $ | 1.1 | $ | 4.8 | $ | 4.6 | ||||||||
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||
|
2010
|
2009
|
2010
|
2009
|
|
|
Risk-free interest rate
|
0.78%
|
1.45%
|
0.78-1.43%
|
1.40-1.45%
|
|
Expected dividend yield
|
-
|
-
|
-
|
-
|
|
Expected volatility
|
75%
|
72%
|
72-75%
|
65-72%
|
|
Expected option life
|
4.1 years
|
4.0 years
|
4-4.1 years
|
3.8-4.0 years
|
|
Weighted-average grant date fair value
|
$3.09
|
$2.71
|
$2.81
|
$1.82
|
|
Options granted
|
6,968
|
16,042
|
773,018
|
1,107,342
|
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
||||
|
2010
|
2009
|
2010
|
2009
|
||
|
(in millions)
|
|||||
|
Numerator:
|
|||||
|
Net income (loss)
|
$1.0
|
$(6.2)
|
$(1.5)
|
$9.0
|
|
|
Net interest expense on convertible notes and convertible preferred stock
dividends (a)
|
-
|
(b)
|
(b)
|
0.2
|
|
|
Net income (loss) if-converted
|
$1.0
|
$(6.2)
|
$(1.5)
|
$9.2
|
|
|
Denominator:
|
|||||
|
Weighted average common shares
|
115.1
|
113.3
|
114.6
|
112.8
|
|
|
Less: Weighted average unvested restricted stock
|
1.9
|
1.5
|
2.0
|
1.5
|
|
|
Denominator for basic calculation
|
113.2
|
111.8
|
112.6
|
111.3
|
|
|
Weighted average effect of dilutive securities:
|
|||||
|
Stock compensation awards
|
0.4
|
(b)
|
(b)
|
0.6
|
|
|
Convertible preferred stock
|
4.7
|
-
|
(b)
|
-
|
|
|
Convertible notes
|
48.1
|
(b)
|
(b)
|
48.1
|
|
|
Denominator for diluted calculation
|
166.4
|
111.8
|
112.6
|
160.0
|
|
|
Net income (loss) per share – basic
|
$.01
|
$(.06)
|
$(.01)
|
$.08
|
|
|
Net income (loss) per share – diluted
|
$.01
|
$(.06) (b)
|
$(.01) (b)
|
$.06
|
|
|
(a)
|
Interest expense on convertible notes and convertible preferred stock dividends net of amount capitalized and net of tax.
|
|
(b)
|
No dilutive effect of convertible notes or stock compensation awards is recognized in a period in which a net loss has occurred.
|
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||
|
2010
|
2009
|
2010
|
2009
|
|
|
Options excluded from diluted earnings per share
|
2.6
|
1.9
|
2.6
|
1.9
|
|
Warrants excluded from diluted earnings per share
|
6.3
|
-
|
6.3
|
-
|
|
Exercise price of excluded options
|
$5.18 to $16.90
|
$5.00 to $16.90
|
$5.18 to $16.90
|
$5.23 to $16.90
|
|
Exercise price of excluded warrants
|
$7.50
|
-
|
$7.50
|
-
|
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2010
|
2009
|
2010
|
2009
|
|||||||||||||
|
(millions)
|
||||||||||||||||
|
Revenue
|
||||||||||||||||
|
LEU segment:
|
||||||||||||||||
|
Separative work units
|
$ | 404.2 | $ | 467.0 | $ | 1,001.8 | $ | 1,266.2 | ||||||||
|
Uranium
|
79.3 | 26.2 | 164.5 | 150.2 | ||||||||||||
| 483.5 | 493.2 | 1,166.3 | 1,416.4 | |||||||||||||
|
U.S. government contracts segment
|
81.1 | 56.1 | 202.7 | 152.8 | ||||||||||||
| $ | 564.6 | $ | 549.3 | $ | 1,369.0 | $ | 1,569.2 | |||||||||
|
Segment Gross Profit
|
||||||||||||||||
|
LEU segment
|
$ | 32.1 | $ | 31.9 | $ | 89.1 | $ | 148.3 | ||||||||
|
U.S. government contracts segment
|
5.9 | 7.3 | 19.7 | 10.5 | ||||||||||||
|
Gross profit
|
38.0 | 39.2 | 108.8 | 158.8 | ||||||||||||
|
Special charge for workforce reduction
|
- | 2.5 | - | 2.5 | ||||||||||||
|
Advanced technology costs
|
28.6 | 31.7 | 80.3 | 93.8 | ||||||||||||
|
Selling, general and administrative
|
14.0 | 14.0 | 43.4 | 45.1 | ||||||||||||
|
Other (income)
|
(12.4 | ) | - | (32.4 | ) | - | ||||||||||
|
Operating income (loss)
|
7.8 | (9.0 | ) | 17.5 | 17.4 | |||||||||||
|
Interest expense (income) and issuance costs, net
|
4.9 | - | 4.8 | (0.2 | ) | |||||||||||
|
Income (loss) before income taxes
|
$ | 2.9 | $ | (9.0 | ) | $ | 12.7 | $ | 17.6 | |||||||
|
·
|
the greater of (1) the JPMorgan Chase Bank prime rate (with a floor of 3%) plus 6.5%, (2) the federal funds rate plus ½ of 1% (with a floor of 3%) plus 6.5%, or (3) an adjusted 1-month LIBO Rate plus 1% (with a floor of 3%) plus 6.5%; or
|
|
·
|
the adjusted LIBO Rate (with a floor of 2%) plus 7.5%.
|
|
·
|
supply LEU to both domestic and international utilities for use in about 150 nuclear reactors worldwide,
|
|
·
|
are deploying what we anticipate will be the world’s most advanced uranium enrichment technology, known as the American Centrifuge,
|
|
·
|
are the exclusive executive agent for the U.S. government under a nuclear nonproliferation program with Russia, known as Megatons to Megawatts,
|
|
·
|
perform contract work for the U.S. Department of Energy (“DOE”) and its contractors at the Paducah and Portsmouth gaseous diffusion plants (“GDPs”), and
|
|
·
|
provide transportation and storage systems for spent nuclear fuel and provide nuclear and energy consulting services.
|
|
·
|
Produced detailed updates to project scope, cost and schedule based on close collaboration with our suppliers;
|
|
·
|
Submitted an update to our DOE loan guarantee application, incorporating the updated project cost and schedule;
|
|
·
|
Closed on the first phase of the $200 million strategic investment by Toshiba and B&W;
|
|
·
|
Initiated discussions with Japanese export credit agencies regarding financing a portion of the cost of building the plant;
|
|
·
|
Operated our lead cascade of production-ready AC100 machines in a commercial plant cascade configuration and accumulated significant runtime;
|
|
·
|
Worked under a March 2010 cooperative agreement with DOE for pro-rata cost sharing support for continued American Centrifuge activities with a total estimated cost of $90 million, including continued operation of the AC100 cascade, manufacturing of additional AC100 centrifuge machines, and refinement to the rotor tube manufacturing process in preparation for full, high-rate production;
|
|
·
|
Refurbished machine positions in the area used for the initial lead cascade with upgraded control systems and instrumentation in preparation for installation of additional AC100 machines during the next several months, which will demonstrate improvements, provide additional data and accumulate additional operating hours; and
|
|
·
|
Continued machine technology development in Oak Ridge in support of lead cascade testing, value engineering and increasing machine productivity.
|
|
·
|
sales of the SWU component of LEU,
|
|
·
|
sales of both the SWU and uranium components of LEU, and
|
|
·
|
sales of uranium.
|
|
September 30,
|
December 31,
|
September 30,
|
||||||||||
|
2010
|
2009
|
2009
|
||||||||||
|
Long-term SWU price indicator ($/SWU)
|
$ | 160.00 | $ | 165.00 | $ | 165.00 | ||||||
|
UF
6
:
|
||||||||||||
|
Long-term price composite ($/KgU)
|
175.00 | 167.77 | 181.59 | |||||||||
|
Spot price indicator ($/KgU)
|
135.00 | 120.00 | 117.00 | |||||||||
|
Nine Months
Ended September 30,
|
Cumulative
as of
September 30,
|
|||||||||||
|
2010
|
2009
|
2010
|
||||||||||
|
Amount expensed
(A)
|
$ | 78.6 | $ | 93.4 | $ | 738.2 | ||||||
|
Amount capitalized
(B
)
|
91.4 | 327.2 | 1,139.7 | |||||||||
|
Total ACP expenditures, including accruals
(C)
|
$ | 170.0 | $ | 420.6 | $ | 1,877.9 | ||||||
|
(A)
Expense included as part of Advanced Technology Costs.
|
||||||||||||
|
(B)
Amounts capitalized as part of property, plant and equipment total $1,086.4 million as of September 30, 2010, including capitalized interest of $68.4 million. Prepayments to suppliers for services not yet performed totaled $34.1 million as of September 30, 2010.
|
||||||||||||
|
(C)
Total ACP expenditures are all American Centrifuge costs including, but not limited to, demonstration facility, licensing activities, commercial plant facility, program management, interest related costs and accrued asset retirement obligations capitalized. This includes $9.5 million of accruals at September 30, 2010.
|
||||||||||||
|
Three Months Ended
September 30,
|
||||||||||||||||
|
2010
|
2009
|
Change
|
%
|
|||||||||||||
|
LEU segment
|
||||||||||||||||
|
Revenue:
|
||||||||||||||||
|
SWU revenue
|
$ | 404.2 | $ | 467.0 | $ | (62.8 | ) | (13 | )% | |||||||
|
Uranium revenue
|
79.3 | 26.2 | 53.1 | 203 | % | |||||||||||
|
Total
|
483.5 | 493.2 | (9.7 | ) | (2 | )% | ||||||||||
|
Cost of sales
|
451.4 | 461.3 | 9.9 | 2 | % | |||||||||||
|
Gross profit
|
$ | 32.1 | $ | 31.9 | $ | 0.2 | 1 | % | ||||||||
|
U.S. government contracts segment
|
||||||||||||||||
|
Revenue
|
$ | 81.1 | $ | 56.1 | $ | 25.0 | 45 | % | ||||||||
|
Cost of sales
|
75.2 | 48.8 | (26.4 | ) | (54 | )% | ||||||||||
|
Gross profit
|
$ | 5.9 | $ | 7.3 | $ | (1.4 | ) | (19 | )% | |||||||
|
Total
|
||||||||||||||||
|
Revenue
|
$ | 564.6 | $ | 549.3 | $ | 15.3 | 3 | % | ||||||||
|
Cost of sales
|
526.6 | 510.1 | (16.5 | ) | (3 | )% | ||||||||||
|
Gross profit
|
$ | 38.0 | $ | 39.2 | $ | (1.2 | ) | (3 | )% | |||||||
|
Nine Months Ended
September 30,
|
||||||||||||||||
|
2010
|
2009
|
Change
|
%
|
|||||||||||||
|
LEU segment
|
||||||||||||||||
|
Revenue:
|
||||||||||||||||
|
SWU revenue
|
$ | 1,001.8 | $ | 1,266.2 | $ | (264.4 | ) | (21 | )% | |||||||
|
Uranium revenue
|
164.5 | 150.2 | 14.3 | 10 | % | |||||||||||
|
Total
|
1,166.3 | 1,416.4 | (250.1 | ) | (18 | )% | ||||||||||
|
Cost of sales
|
1,077.2 | 1,268.1 | 190.9 | 15 | % | |||||||||||
|
Gross profit
|
$ | 89.1 | $ | 148.3 | $ | (59.2 | ) | (40 | )% | |||||||
|
U.S. government contracts segment
|
||||||||||||||||
|
Revenue
|
$ | 202.7 | $ | 152.8 | $ | 49.9 | 33 | % | ||||||||
|
Cost of sales
|
183.0 | 142.3 | (40.7 | ) | (29 | )% | ||||||||||
|
Gross profit
|
$ | 19.7 | $ | 10.5 | $ | 9.2 | 88 | % | ||||||||
|
Total
|
||||||||||||||||
|
Revenue
|
$ | 1,369.0 | $ | 1,569.2 | $ | (200.2 | ) | (13 | )% | |||||||
|
Cost of sales
|
1,260.2 | 1,410.4 | 150.2 | 11 | % | |||||||||||
|
Gross profit
|
$ | 108.8 | $ | 158.8 | $ | (50.0 | ) | (31 | )% | |||||||
|
Three Months Ended
September 30,
|
||||||||||||||||
|
2010
|
2009
|
Change
|
%
|
|||||||||||||
|
Gross profit
|
$ | 38.0 | $ | 39.2 | $ | (1.2 | ) | (3 | )% | |||||||
|
Special charge for workforce reduction
|
- | 2.5 | 2.5 | 100 | % | |||||||||||
|
Advanced technology costs
|
28.6 | 31.7 | 3.1 | 10 | % | |||||||||||
|
Selling, general and administrative
|
14.0 | 14.0 | - | - | ||||||||||||
|
Other (income)
|
(12.4 | ) | - | 12.4 | - | |||||||||||
|
Operating income (loss)
|
7.8 | (9.0 | ) | 16.8 | 187 | % | ||||||||||
|
Preferred stock issuance costs
|
4.8 | - | (4.8 | ) | - | |||||||||||
|
Interest expense
|
0.3 | 0.2 | (0.1 | ) | (50 | )% | ||||||||||
|
Interest (income)
|
(0.2 | ) | (0.2 | ) | - | - | ||||||||||
|
Income (loss) before income taxes
|
2.9 | (9.0 | ) | 11.9 | 132 | % | ||||||||||
|
Provision (benefit) for income taxes
|
1.9 | (2.8 | ) | (4.7 | ) | (168 | )% | |||||||||
|
Net income (loss)
|
$ | 1.0 | $ | (6.2 | ) | $ | 7.2 | 116 | % | |||||||
|
Nine Months Ended
September 30,
|
||||||||||||||||
|
2010
|
2009
|
Change
|
%
|
|||||||||||||
|
Gross profit
|
$ | 108.8 | $ | 158.8 | $ | (50.0 | ) | (31 | )% | |||||||
|
Special charge for workforce reduction
|
- | 2.5 | 2.5 | 100 | % | |||||||||||
|
Advanced technology costs
|
80.3 | 93.8 | 13.5 | 14 | % | |||||||||||
|
Selling, general and administrative
|
43.4 | 45.1 | 1.7 | 4 | % | |||||||||||
|
Other (income)
|
(32.4 | ) | - | 32.4 | - | |||||||||||
|
Operating income
|
17.5 | 17.4 | 0.1 | 1 | % | |||||||||||
|
Preferred stock issuance costs
|
4.8 | - | (4.8 | ) | - | |||||||||||
|
Interest expense
|
0.4 | 1.0 | 0.6 | 60 | % | |||||||||||
|
Interest (income)
|
(0.4 | ) | (1.2 | ) | (0.8 | ) | (67 | )% | ||||||||
|
Income before income taxes
|
12.7 | 17.6 | (4.9 | ) | (28 | )% | ||||||||||
|
Provision for income taxes
|
14.2 | 8.6 | (5.6 | ) | (65 | )% | ||||||||||
|
Net income (loss)
|
$ | (1.5 | ) | $ | 9.0 | $ | (10.5 | ) | (117 | )% | ||||||
|
·
|
Changes to the electric power fuel cost adjustment from our current projection;
|
|
·
|
The timing of recognition of previously deferred revenue, particularly related to the sale of uranium;
|
|
·
|
Changes to planned spending on the American Centrifuge project;
|
|
·
|
Movement and timing of customer orders;
|
|
·
|
Changes to SWU and uranium price indicators, and changes in inflation that can affect the price of SWU billed to customers;
|
|
·
|
Economics of underfeeding the production process at the Paducah GDP to make additional uranium sales; and
|
|
·
|
Actions taken by governmental bodies or agencies.
|
|
Nine Months Ended
September 30,
|
||||||||
|
2010
|
2009
|
|||||||
|
Net Cash Provided by (Used in) Operating Activities
|
$ | 30.0 | $ | 319.4 | ||||
|
Net Cash (Used in) Investing Activities
|
(74.9 | ) | (401.4 | ) | ||||
|
Net Cash Provided by (Used in) Financing Activities
|
59.7 | (97.2 | ) | |||||
|
Net Increase (Decrease) in Cash and Cash Equivalents
|
$ | 14.8 | $ | (179.2 | ) | |||
|
September 30,
|
December 31,
|
|||||||
|
2010
|
2009
|
|||||||
|
(millions)
|
||||||||
|
Cash and cash equivalents
|
$ | 146.1 | $ | 131.3 | ||||
|
Accounts receivable, net
|
228.0 | 191.4 | ||||||
|
Inventories, net
|
885.7 | 831.8 | ||||||
|
Other current assets and liabilities, net
|
(328.1 | ) | (267.5 | ) | ||||
|
Working capital
|
$ | 931.7 | $ | 887.0 | ||||
|
·
|
the greater of (1) the JPMorgan Chase Bank prime rate (with a floor of 3%) plus 6.5%, (2) the federal funds rate plus ½ of 1% (with a floor of 3%) plus 6.5%, or (3) an adjusted 1-month LIBO Rate plus 1% (with a floor of 3%) plus 6.5%; or
|
|
·
|
the adjusted LIBO Rate (with a floor of 2%) plus 7.5%.
|
|
|
·
|
the sum of (1) the greater of a) the JPMorgan Chase Bank prime rate, b) the federal funds rate plus ½ of 1%, or c) an adjusted 1-month LIBO Rate plus 1% plus (2) a margin ranging from 2.25% to 2.75% based upon availability, or
|
|
|
·
|
the sum of the adjusted LIBO Rate plus a margin ranging from 4.0% to 4.5% based upon availability.
|
|
September 30,
|
December 31,
|
|||||||
|
2010
|
2009
|
|||||||
|
Short-term borrowings
|
$ | - | $ | - | ||||
|
Letters of credit
|
42.6 | 45.4 | ||||||
|
Available credit
|
207.4 | 295.5 | ||||||
|
December 31,
2009
|
Expenditures
|
Amortization
|
September 30,
2010
|
|||||||||||||
|
Other current assets:
|
||||||||||||||||
|
Bank credit facilities
|
$ | 0.5 | $ | 8.4 | $ | (2.6 | ) | $ | 6.3 | |||||||
|
Deferred financing costs (long-term):
|
||||||||||||||||
|
Convertible notes
|
$ | 10.0 | $ | - | $ | (1.5 | ) | $ | 8.5 | |||||||
|
DOE Loan Guarantee application
|
2.0 | - | - | 2.0 | ||||||||||||
|
Deferred financing costs
|
$ | 12.0 | $ | - | $ | (1.5 | ) | $ | 10.5 | |||||||
|
Financial Assurance
|
Long-Term Liability
|
|||||||||||||||
|
September 30
,
2010
|
December 31,
2009
|
September 30
,
2010
|
December 31,
2009
|
|||||||||||||
|
Depleted uranium disposition and stored wastes
|
$ | 189.2 | $ | 262.8 | $ | 119.2 | $ | 155.6 | ||||||||
|
Decontamination and decommissioning of American Centrifuge
|
22.2 | 22.2 | 22.3 | 21.3 | ||||||||||||
|
Other financial assurance
|
17.6 | 20.4 | ||||||||||||||
|
Total financial assurance
|
$ | 229.0 | $ | 305.4 | ||||||||||||
|
Letters of credit
|
42.6 | 45.4 | ||||||||||||||
|
Surety bonds
|
186.4 | 260.0 | ||||||||||||||
|
Cash collateral deposit for surety bonds
|
$ | 110.2 | $ | 158.3 | ||||||||||||
|
|
•
|
commodity price risk for electric power requirements for the Paducah GDP (refer to “Overview – Cost of Sales” and “Results of Operations – Cost of Sales”),
|
|
|
•
|
interest rate risk relating to the outstanding term loan and any outstanding borrowings at variable interest rates under our credit facility (refer to “Liquidity and Capital Resources – Capital Structure and Financial Resources”), and
|
|
|
•
|
interest rate and other market risks relating to the valuation of our convertible preferred stock (refer to “Liquidity and Capital Resources – Capital Structure and Financial Resources”).
|
|
·
|
Completing a review of our quality assurance program and implementing corrective actions as needed;
|
|
·
|
Startup and operations of the AC100 lead cascade testing program in early 2010 using upgraded production machines to improve DOE’s confidence in the machines’ reliability through consistent operation;
|
|
·
|
Maintaining and demonstrating centrifuge machine manufacturing capability; and
|
|
·
|
Establishing a revised baseline cost and schedule for the project, taking into account the demobilization and remobilization costs and associated delays.
|
|
·
|
We have incurred and will incur significant costs and expenses relating to the Transactions, whether or not the remaining Transactions are completed;
|
|
·
|
Matters relating to the Transactions require substantial commitments of time and resources by our management, whether or not the remaining Transactions are completed, which could otherwise have been devoted to other opportunities that may have been beneficial to us, including pursuing other strategic options or sources of capital;
|
|
·
|
The second closing of the Transactions is conditioned on our obtaining a conditional commitment for a loan guarantee of not less than $2 billion from DOE. The securities purchase agreement may be terminated by any party if the second closing does not occur by June 30, 2011. If the second closing is not consummated, our ability to continue to spend on the American Centrifuge project will be limited and our anticipated sources of near term liquidity could be affected;
|
|
·
|
Our loan guarantee application includes the $200 million investment as part of the sources of funds for the American Centrifuge project. The strategic investment was also intended in part to address financial concerns of the DOE with respect to the ability of the American Centrifuge project to mitigate cost and other risk. If the remaining Transactions are not consummated or are delayed significantly, this would adversely affect our ability to obtain a loan guarantee (which is a condition to the third closing);
|
|
·
|
We need significant additional financing to complete construction of the American Centrifuge Plant beyond the DOE loan guarantee and the proceeds of the Transactions, and we will need to demonstrate the availability of that funding in order to obtain the DOE loan guarantee (which is a condition of the third closing). We have initiated discussions with Japanese export credit agencies (ECAs) for additional financing. Our ability to obtain Japanese ECA financing is highly dependent on the strategic investment by Toshiba. If the remaining Transactions are not consummated or are delayed significantly and our ability to obtain Japanese ECA financing is adversely affected, this will subsequently adversely affect our ability to obtain a DOE loan guarantee, consummate the third closing and complete the American Centrifuge project; and
|
|
·
|
If the remaining Transactions are not consummated, we may be unable to raise capital from alternative sources on terms favorable to us, if at all. If the remaining Transactions are not consummated or are delayed significantly and we are unable to raise capital from alternative sources, our business and prospects (including the American Centrifuge project) may be substantially harmed and our stock price may decline.
|
|
·
|
Success in potential efforts to sell our low enriched uranium in connection with Toshiba’s nuclear power plant proposals, including Toshiba’s success in nuclear reactor sales;
|
|
·
|
Success of efforts to identify potential growth opportunities in U.S. government services, spent nuclear fuel transportation and storage, manufacturing of spent fuel storage systems; and
|
|
·
|
Our success in achieving cost savings and other benefits through the manufacturing joint venture with B&W.
|
|
·
|
our ability to get loan guarantees or other support from the U.S. government,
|
|
·
|
our ability to meet the closing conditions of the second and third phases of the $200 million strategic transaction with Toshiba and B&W and to otherwise address the financial concerns identified by DOE,
|
|
·
|
the success of any discussions with Japanese export credit agencies regarding financing for the American Centrifuge project, including our dependency on Toshiba’s support for these discussions,
|
|
·
|
the success of our demonstration of the American Centrifuge technology and our ability to address the technical concerns and risks identified by DOE,
|
|
·
|
the estimated costs, efficiency, timing and return on investment of the deployment of the American Centrifuge Plant (described below),
|
|
·
|
our ability to secure a sufficient number of long-term SWU purchase commitments from customers on satisfactory terms, including adequate prices,
|
|
·
|
the level of success of our current operations,
|
|
·
|
SWU prices,
|
|
·
|
USEC’s perceived competitive position and investor confidence in our industry and in us,
|
|
·
|
projected costs for the disposal of depleted uranium and the decontamination and decommissioning of the American Centrifuge Plant, and the impact of related financial assurance requirements,
|
|
·
|
additional downgrades in our credit rating,
|
|
·
|
market price and volatility of our common stock,
|
|
·
|
general economic and capital market conditions,
|
|
·
|
conditions in energy markets,
|
|
·
|
regulatory developments,
|
|
·
|
our reliance on LEU delivered to us under the Russian Contract and uncertainty regarding prices and deliveries under the Russian Contract, and
|
|
·
|
restrictive covenants in the agreements governing our credit facility and in our outstanding notes and any future financing arrangements that limit our operating and financial flexibility.
|
|
·
|
November 2010 – Secure firm financing commitment(s) for the construction of the commercial American Centrifuge Plant with an annual capacity of approximately 3.5 million SWU per year (the “Financing Milestone”);
|
|
·
|
August 2010 – begin commercial American Centrifuge Plant operations;
|
|
·
|
November 2011 – commercial American Centrifuge Plant annual capacity at 1 million SWU per year; and
|
|
·
|
May 2013 – commercial American Centrifuge Plant annual capacity of approximately 3.5 million SWU per year.
|
|
·
|
The potential impact on USEC employees and potential severance and other costs to USEC, as we have approximately 1,100 employees working at the former Portsmouth plant supporting DOE, its activities and the cold shutdown contract efforts;
|
|
·
|
The potential impact of the loss of employees on work we perform to comply with requirements of our certificate with NRC for the Portsmouth facility;
|
|
·
|
The potential impact of our de-lease of facilities at Portsmouth on our activities with respect to the American Centrifuge plant, including, but not limited to, potential reduction in flexibility with respect to the storage of materials, potential increased costs of site services and use of site facilities, and potential increased interferences with our activities on site;
|
|
·
|
The potential impact on our ability to collect unbilled amounts from DOE. As a part of performing contract work for DOE, certain contractual issues, scope of work uncertainties, and various disputes arise from time to time. As discussed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Revenue from U.S. Government Contracts,” we believe that as of September 30, 2010 additional amounts can be billed to DOE and revenue of approximately $2.3 million may be recognizable. There could also be the potential for additional revenue to be recognized related to our valuation allowances pending the outcome of DCAA audits and DOE reviews. In addition, $31.2 million of unbilled receivables and $6.5 million of past due receivables related directly to DOE or DOE contractors remain on our consolidated balance sheet as of September 30, 2010, and the timing and amount of recovery are uncertain. The termination of the cold shutdown contract could adversely affect our ability to timely recover these or other amounts we may be owed from DOE; and
|
|
·
|
The potential impact on the cost of remaining services and activities. The reduction of the scope of work performed by USEC for DOE and the transition of the work to the D&D contractor could adversely impact the costs to us at the Portsmouth site and throughout the rest of the Company. Costs of work self-performed by us could increase due to the increased allocation of overhead and other costs to such work. Costs of contracting with the D&D contractor to perform work previously performed by us could be higher than current costs.
|
|
(c) Total Number
|
(d) Maximum Number
|
|||||||
|
(a) Total
|
(b)
|
of Shares (or Units)
|
(or Approximate Dollar
|
|||||
|
Number of
|
Average
|
Purchased as Part
|
Value) of Shares (or
|
|||||
|
Shares (or
|
Price Paid
|
of Publicly
|
Units) that May Yet Be
|
|||||
|
Units)
|
Per Share
|
Announced Plans
|
Purchased Under the
|
|||||
|
Period
|
Purchased(1)
|
(or Unit)
|
or Programs
|
Plans or Programs
|
||||
|
July 1 – July 31
|
-
|
$ -
|
-
|
-
|
||||
|
August 1 – August 31
|
3,414
|
$5.07
|
-
|
-
|
||||
|
September 1 – September 30
|
2,078
|
$5.08
|
-
|
-
|
||||
|
Total
|
5,492
|
$5.07
|
-
|
-
|
|
(1)
|
These purchases were not made pursuant to a publicly announced repurchase plan or program. Represents 5,492 shares of common stock surrendered to USEC to pay withholding taxes on shares of restricted stock under the Company’s equity incentive plan.
|
|
|
3.1
|
Certificate of
Incorporation of USEC Inc., as amended
.
|
|
|
4.1
|
Warrant to purchase 3,125,000 shares of Class B Common Stock or 3,125 shares of Series C Convertible Participating Preferred Stock issued to Toshiba America Nuclear Energy Corporation, incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K filed on September 2, 2010 (Commission file number 1-14287).
|
|
|
4.2
|
Warrant to purchase 3,125,000 shares of Class B Common Stock or 3,125 shares of Series C Convertible Participating Preferred Stock issued to Babcock & Wilcox Investment Company, incorporated by reference to Exhibit 4.2 of the Current Report on Form 8-K filed on September 2, 2010 (Commission file number 1-14287).
|
|
|
10.1
|
Investor Rights Agreement, dated as of September 2, 2010, by and among USEC Inc., Toshiba Corporation, and Babcock & Wilcox Investment Company, incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed on September 2, 2010 (Commission file number 1-14287).
|
|
|
10.2
|
Limited Liability Company Agreement of American Centrifuge Manufacturing, LLC dated as of September 2, 2010 between American Centrifuge Holdings, LLC and Babcock & Wilcox Technical Services Group, Inc., incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed on September 2, 2010 (Commission file number 1-14287) (Certain information has been omitted and filed separately pursuant to a request for confidential treatment under Rule 24b-2).
|
|
|
31.1
|
Certification of the Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a).
|
|
|
31.2
|
Certification of the Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a).
|
|
|
32
|
Certification of CEO and CFO pursuant to 18 U.S.C. Section 1350.
|
|
|
101.INS
|
XBRL Instance Document
|
|
|
101.SCH
|
XBRL Taxonomy Extension Schema Document
|
|
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
USEC Inc.
|
|||
|
November 3, 2010
|
By:
|
/s/ John C. Barpoulis
|
|
|
John C. Barpoulis
|
|||
|
Senior Vice President and Chief Financial Officer
|
|||
|
(Principal Financial Officer)
|
|||
|
3.1
|
Certificate of Incorporation of USEC Inc., as amended.
|
|
4.1
|
Warrant to purchase 3,125,000 shares of Class B Common Stock or 3,125 shares of Series C Convertible Participating Preferred Stock issued to Toshiba America Nuclear Energy Corporation, incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K filed on September 2, 2010 (Commission file number 1-14287).
|
|
4.2
|
Warrant to purchase 3,125,000 shares of Class B Common Stock or 3,125 shares of Series C Convertible Participating Preferred Stock issued to Babcock & Wilcox Investment Company, incorporated by reference to Exhibit 4.2 of the Current Report on Form 8-K filed on September 2, 2010 (Commission file number 1-14287).
|
|
10.1
|
Investor Rights Agreement, dated as of September 2, 2010, by and among USEC Inc., Toshiba Corporation, and Babcock & Wilcox Investment Company, incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed on September 2, 2010 (Commission file number 1-14287).
|
|
10.2
|
Limited Liability Company Agreement of American Centrifuge Manufacturing, LLC dated as of September 2, 2010 between American Centrifuge Holdings, LLC and Babcock & Wilcox Technical Services Group, Inc., incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed on September 2, 2010 (Commission file number 1-14287) (Certain information has been omitted and filed separately pursuant to a request for confidential treatment under Rule 24b-2).
|
|
31.1
|
Certification of the Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a).
|
|
31.2
|
Certification of the Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a).
|
|
32
|
Certification of CEO and CFO pursuant to 18 U.S.C. Section 1350.
|
|
101.INS
|
XBRL Instance Document
|
|
101.SCH
|
XBRL Taxonomy Extension Schema Document
|
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|